AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (438.3 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Perspective | Open Access

Rethinking anti-cancer drug discovery: the evolution from polypharmacy to unified drug units

Jun He1, Xinbing Sui1,2 ( )
Department of Medical Oncology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, China
School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China
Show Author Information

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Biology & Medicine
Volume 23 Issue 1,
January 2026
Pages 15-20
DOI: 10.20892/j.issn.2095-3941.2025.0641

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
He J, Sui X. Rethinking anti-cancer drug discovery: the evolution from polypharmacy to unified drug units. Cancer Biology & Medicine, 2026, 23(1): 15-20. https://doi.org/10.20892/j.issn.2095-3941.2025.0641

275

Views

17

Downloads

1

Crossref

1

Web of Science

0

Scopus
Received: 24 October 2025
Accepted: 03 December 2025
Published: 29 January 2026
©2026 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)